Apr 27, 2021

Featuring Dr Mark Levis’s perspectives on his time spent speaking with patients with acute myeloid leukemia from the practice of community oncologist Dr Spencer Bachow, including the following topics:

• Case: A woman in her early 70s with acute myeloid leukemia (AML) and mutations in FLT3, NPM1 and IDH1 receives standard induction therapy and midostaurin followed by an allogeneic stem cell transplant (0:00)
• Perspective on the choice of allogeneic stem cell transplant versus venetoclax with a hypomethylating agent for older patients with AML; therapeutic options for post-transplant maintenance therapy (4:00)
• Selection of therapy for an older patient with AML with FLT3 and IDH mutations (15:13)
• Case: A man in his mid-70s with multiple comorbidities is diagnosed with AML with an SRSF2 mutation and receives azacitidine and venetoclax followed by venetoclax alone (24:47)
• Benefits and risks with the combination of venetoclax and azacitidine for patients with AML (34:49)
• Selection of patients for oral azacitidine; FDA approval of oral azacitidine as maintenance therapy for patients with AML in first remission (42:27)
• Case: A man in his late 40s with a history of primary myelofibrosis is diagnosed with secondary AML with del(5q) and del(7q) and mutations in JAK2 V617F, IDH2, DNMT3A and SRSF2 (45:55)
• Risk factors for the development of AML; therapeutic options for a patient with AML and mutations in JAK2 V617F, IDH2, DNMT3A and SRSF2 (51:08)
• Choice between venetoclax in combination with a hypomethylating agent and a clinical trial of CPX-351 (liposomal daunorubicin with cytarabine), each in combination with an IDH inhibitor, for patients with AML and an IDH mutation (55:36)
• Activity and tolerability of liposomal daunorubicin with cytarabine and its FDA approval for patients with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (1:02:00)

CME information and select publications